作者
Toshiaki Ara, Ken-ichi Honjo, Yoshiaki Fujinami, Toshimi Hattori, Yasuhiro Imamura, Pao-Li Wang
发表日期
2010/4/1
期刊
Biological and Pharmaceutical Bulletin
卷号
33
期号
4
页码范围
611-616
出版商
The Pharmaceutical Society of Japan
简介
MATERIALS AND METHODS
Reagents Powder of Orento was obtained from Tsumura & Co.(Tokyo, Japan), and its components were indicated in Table 1. Orento was suspended in Dulbecco’s modified Eagle’s medium (D-MEM, Sigma, St. Louis, MO, USA) containing 10% heat-inactivated fetal calf serum, 100 units/ml penicillin and 100mg/ml streptomycin (culture medium) and was rotated at 4 C overnight. Then, the suspension was centrifuged and the supernatant was filtrated through 0.45 mm-pore membrane. LPS from Porphyromonas gingivalis 381 (PgLPS) was provided by Drs. Tatsuji Nishihara and Nobuhiro Hanada (National Institutes of Public Health, Wako, Japan). Phorbol 12-myristate 13-acetate (PMA) and PD98059 [mitogen-activated protein kinase kinase (MAPKK/MEK) inhibitor] were purchased from Sigma and dissolved in dimethyl sulfoxide (DMSO). Arachidonic acid solution (from porcine liver) was purchased from Sigma. The anti-
引用总数
20102011201220132014201520162017201820192020202120222023111745323411
学术搜索中的文章